Japan pharmaceuticals and biotech sector: Apr–Jun results at Novartis Quick Note

Research evidence excerpt

Japan pharmaceuticals and biotech sector: Apr–Jun results at Novartis Quick Note

Nomura | Japan pharmaceuticals and biotech sector 22 July 2026

NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be

guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain

viruses. The sender therefore does not accept liability (in negligence or otherwise, and in whole or in part) for any errors or omissions in the

contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Disclaimers required in Japan

Credit ratings in the text that are marked with an asterisk (*) are issued by a rating agency not registered under Japan’s Financial Instruments

and Exchange Act (“Unregistered Ratings”). For details on Unregistered Ratings, please contact the Research Production Operation Dept. of

Nomura Securities Co., Ltd.

Investors in the financial products offered by Nomura Securities may incur fees and commissions specific to those products (for example,

transactions involving Japanese equities are subject to a sales commission (all figures on a tax-inclusive basis) of up to 1.43% of the transaction

amount or a commission of ¥2,860 for transactions of ¥200,000 or less, while transactions involving investment trusts are subject to various

fees, such as commissions at the time of purchase and asset management fees, such as commissions at the time of purchase and asset

management fees (trust fees), specific to each investment trust).

In addition, all products carry the risk of losses owing to price fluctuations or other factors. Fees and risks vary by product.